LTR Pharma (ASX:LTP) Issuance of Debt: A$0.00 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:LTP LTR Pharma Ltd ASX:LTP
12 GF Score
Price A$0.49
View Full Analysis

What is LTR Pharma Issuance of Debt?

LTR Pharma ASX:LTP -1.02% 12 Issuance of Debt is A$0.00 Mil as of Dec. 2025. GuruFocus rates ASX:LTP with a GF Score™ of 12/100.

LTR Pharma's Issuance of Debt for the six months ended in Dec. 2025 was A$0.00 Mil.

LTR Pharma's Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.00 Mil.

LTR Pharma Issuance of Debt Related Terms

LTR Pharma Issuance of Debt Historical Data

* Premium members only.

The historical data trend for LTR Pharma's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LTR Pharma Issuance of Debt Chart

LTR Pharma Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
Issuance of Debt
0.35 0.00 0.00 0.00 0.00

LTR Pharma Semi-Annual Data
Jun21 Jun22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Issuance of Debt Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
ASX:LTP
12GF Score
LTR Pharma Ltd ASX:LTP
Issuance of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LTR Pharma Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Issuance of Debt →
What does a Issuance of Debt of A$0.00 Mil mean?
LTR Pharma (ASX:LTP) has a Issuance of Debt of A$0.00 Mil as of Dec. 2025. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on LTR Pharma and its competitors.
Is LTR Pharma's Issuance of Debt too high?
LTR Pharma's current Issuance of Debt is A$0.00 Mil. Overall, LTR Pharma has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does LTR Pharma's Issuance of Debt compare to VRTX and REGN?
LTR Pharma's Issuance of Debt of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Issuance of Debt for a Biotechnology company?
A good Issuance of Debt depends on the Biotechnology industry context. However, Issuance of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Issuance of Debt mean?
A high Issuance of Debt can signal that a stock is expensive relative to its fundamentals. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on LTR Pharma and its competitors. LTR Pharma's current Issuance of Debt is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LTR Pharma stock overvalued right now?
LTR Pharma (ASX:LTP) has a current Issuance of Debt of A$0.00 Mil. The current Issuance of Debt is A$0.00 Mil. LTR Pharma's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Issuance of Debt calculated?
Issuance of Debt is calculated from a company's financial statements. For LTR Pharma (ASX:LTP), the current Issuance of Debt is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LTR Pharma Business Description

Address 9A/204 Alice Street, Brisbane, QLD, AUS, 4000
LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on the market.
12GF Score

Get the complete analysis for ASX:LTP

Issuance of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.49
Price